ML20137J211

From kanterella
Jump to navigation Jump to search
Supports Use of ACMUI & Professional Medical Organizations & Societies That Was Proposed in Commissions Preliminary Views Re DSI-7, Matls/Medical Oversight
ML20137J211
Person / Time
Issue date: 02/21/1997
From: Rogers K
NRC COMMISSION (OCM)
To: Diaz N, Dicus G, Shirley Ann Jackson, Mcgaffigan E, The Chairman
NRC COMMISSION (OCM)
Shared Package
ML20137J180 List:
References
COMSECY-96-057, COMSECY-96-57, DSI-7, SECY-96-057-C, SECY-96-57-C, NUDOCS 9704030244
Download: ML20137J211 (1)


Text

. - - -

/>RRECy l

'o UNITED STATES

            • '*******eeoeoea,,,
5. y "g

NUCLEAR REGULATORY COMMISSION REl_ EASED TO THE PDR l

1

e W ASHINGTON, D.C. 20555 b-l kk cats ingja!3

....+

OFFICE OF THE cOuuissioNEn January 21,1997 i

4 MEMORANDUM TO:

Chairman Jackson Commissioner Dieus Commissioner Diaz l

Commissioner McGaffigan 1

FROM:

Commissioner Rogers Q,

l i

i

SUBJECT:

COMSECY-g6 057: MATERIALS / MEDICAL OVERSIGHT - DSI-7 After a review of the Phase ll Stakeholder interschon Report and after listening to the Steering l

Committee briefing ori January 13, I beheve the Commission's preisminary views on this DSI capture my position relative to NRC's regulabon of Atomic Energy Act (AEA) materials and, in

' particular, its program for medical use of those materials. More specifically, I still favor a l

combination of Option 2 (Continue the ongoing program with improvements) and Ophon 3 (Decrease oversight of low-risk activities with continued emphasis of high-risk schvities). I also continue to support the use of ACMUI and professional medical organizations and societies that was proposed in the Commission's preliminary views.

i I believe that the changes to 10 CFR Part 35 that would be needed to implement the Commission's views should be accornplished through an enhanced participatory process. This 1

would allow a full exploration of views regarding the application of a risk-informed, performance-based approach to NRC's oversight of medical activities. A significant number of commenters i

favored an expansion of the scope of NRC regulation to include all medical use of rachation.

While i do not object to this issue being further considered in conjunchon with an enhanced

]

participatory rulemaking process, I would not favor re-opening the AEA solely for the purpose of j

such an expansion (however, if NRC were to be given broader oversight over OOE, the authorizing legislation might be used as a vehicle).V'^-

j i

J i

i cc:

EDO j

OGC j

SECY e

+

d 1

l 9704030244 970401 PDR NRCSA I

.